Condition: Endometrial Cancer · Recurrent Endometrial Cancer · TP53 · Sponsor: Dana-Farber Cancer Institute
The purpose of this research study is to see if the study drugs abemaciclib and letrozole are effective and safe for participants with estrogen-receptor positive (ER+), mismatch repair proficient, tumor protein p53 (TP53) wild-type endometrial cancer. The names of the study drugs involved in this study are: * Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor) * Letrozole (a type of aromatase inhibitor)
This description comes directly from the study's public registry record.
Panagiotis Konstantinopoulos, MD, PhD · 617-632-2334 · Panagiotis_Konstantinopoulos@DFCI.HARVARD.EDU
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute at Foxborough | Foxborough, Massachusetts, United States | Withdrawn |
| Dana-Farber Cancer Institute at Milford | Milford, Massachusetts, United States | Withdrawn |
| Dana-Farber Cancer Institute at South Shore Hospital | Weymouth, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06366347